On May 18, 2022 Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, reported that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022 (Press release, Chemomab, MAY 18, 2022, View Source [SID1234614798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HC Wainwright Global Investment Conference

Date: Webcast available on demand starting at 7:00am ET May 24 – May 26, 2022

Format: Corporate overview webcast

Webcast Link: View Source

Replay: Available at Chemomab website at investors.chemomab.com/events

Chemomab is also participating in one-on-one meetings with investors. For more information, visit hcwevents.com/globalconference/.